Although a meta-analysis has shown that tumoral PD-L1 expression is associated with a poor prognosis in patients with breast cancer (HR, 1.63; 95% CI, 1.07–2.46; p = 0.02), this study has failed to demonstrate any significant HR between tumoral PD-L1 expression and a better prognosis in TNBC patients. This evidence concerns the gene CD274 and breast carcinoma.